The National Institute for Health and Clinical Excellence (NICE), UK, has issued draft guidance on DySIS Medical's cervical cancer screening product for public consultation.
The DySIS colposcopy employs photonics and computer assistance to quantify and map the acetowhitening process, providing clinicians with information to help identify pre-cancerous lesions.
The draft guidance also reported that the sensitivity of DySIS was found to be 77.4% in the subgroup of women referred to colposcopy with low-grade cytology, compared to 19.4% with conventional colposcopy.
In previous clinical trials, the colposcopy has been shown to considerably improve sensitivity in detecting cervical cancer in early stages, enabling clinicians to treat patients and prevent disease progression.
The NICE committee suggested the DySIS colposcopy is a cost-effective option for examining the uterine cervix in women referred for colposcopy, and should be considered in procurement plans when replacing colposcopy equipment.
DySIS Medical CEO Alastair Atkinson said an important feature of the report was the acknowledgement that DySIS delivers a better standard of care for women at a lower overall cost, which is supported by the company's observations in other key international markets.
Whittington Hospital Consultant Gynaecologist MRCOG Theresa Freeman Wang, who has been using DySIS, said the extra sensitivity DySIS delivers could be helpful in detecting the smaller pre-cancerous lesions which require treatment, and may assist in safely reducing the need for colposcopy follow-up appointments. The company's colposcopy is commercially available in Europe and the US.
Image: The colposcopy of DySIS has been granted positive draft guidance by NICE. Photo: DySIS Medical.